Dr. Padua has 156 years of experience in the medical device industry. He has participated in research projects to administer preclinical studies as well as pre- and post-market clinical studies.
St. Teresa is moving forward with commercialization of its new hemostatic technology platform — ORTHOCLOT — and Dr. Padua will play a central role in developing and executing the clinical plan and procedures for the human trial in Europe.
More articles on orthopedic devices:
Exactech director sells 8k shares in $410k transaction
Medtronic tax inversion strategy profitable for two top Republicans
Medtech investment: 8 observations on future growth
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
